JP2011513221A - テトラヒドロフロピリドン - Google Patents

テトラヒドロフロピリドン Download PDF

Info

Publication number
JP2011513221A
JP2011513221A JP2010547685A JP2010547685A JP2011513221A JP 2011513221 A JP2011513221 A JP 2011513221A JP 2010547685 A JP2010547685 A JP 2010547685A JP 2010547685 A JP2010547685 A JP 2010547685A JP 2011513221 A JP2011513221 A JP 2011513221A
Authority
JP
Japan
Prior art keywords
hydroxy
oxo
carbonyl
glycine
tetrahydrothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010547685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513221A5 (enExample
Inventor
コランドレーア，ビンセント・ジエイ
ヘイル，ジエフリー・ジエイ
マツコイ，ジヨシユア・ジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2011513221A publication Critical patent/JP2011513221A/ja
Publication of JP2011513221A5 publication Critical patent/JP2011513221A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010547685A 2008-02-25 2009-02-11 テトラヒドロフロピリドン Pending JP2011513221A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6697908P 2008-02-25 2008-02-25
PCT/US2009/033713 WO2009108496A1 (en) 2008-02-25 2009-02-11 Tetrahydrofuropyridones

Publications (2)

Publication Number Publication Date
JP2011513221A true JP2011513221A (ja) 2011-04-28
JP2011513221A5 JP2011513221A5 (enExample) 2012-03-29

Family

ID=41016431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010547685A Pending JP2011513221A (ja) 2008-02-25 2009-02-11 テトラヒドロフロピリドン

Country Status (7)

Country Link
US (1) US8471024B2 (enExample)
EP (1) EP2257170B1 (enExample)
JP (1) JP2011513221A (enExample)
CN (1) CN101951777A (enExample)
AU (1) AU2009217540B2 (enExample)
CA (1) CA2716798A1 (enExample)
WO (1) WO2009108496A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134750A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
HUE052128T2 (hu) 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
CN104507910B (zh) 2012-07-30 2016-06-15 大正制药株式会社 部分饱和的含氮杂环化合物
MY175854A (en) * 2012-12-24 2020-07-14 Cadila Healthcare Ltd Novel quinolone derivatives
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
WO2016045128A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045127A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045126A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110305143B (zh) * 2019-07-19 2021-03-09 济南新科医药科技有限公司 一种呋喃[2，3-c]并吡啶衍生物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2008137060A1 (en) * 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
JP2008546644A (ja) * 2005-06-06 2008-12-25 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
JP2009519249A (ja) * 2005-12-09 2009-05-14 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
JP2009529536A (ja) * 2006-03-07 2009-08-20 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害薬
JP2009537558A (ja) * 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546644A (ja) * 2005-06-06 2008-12-25 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
JP2009519249A (ja) * 2005-12-09 2009-05-14 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
JP2009529536A (ja) * 2006-03-07 2009-08-20 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害薬
JP2009537558A (ja) * 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
WO2008137060A1 (en) * 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity

Also Published As

Publication number Publication date
CN101951777A (zh) 2011-01-19
CA2716798A1 (en) 2009-09-03
EP2257170A4 (en) 2011-08-03
WO2009108496A1 (en) 2009-09-03
EP2257170B1 (en) 2012-12-26
AU2009217540B2 (en) 2013-10-10
EP2257170A1 (en) 2010-12-08
US8471024B2 (en) 2013-06-25
AU2009217540A1 (en) 2009-09-03
US20100331358A1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
JP2011513221A (ja) テトラヒドロフロピリドン
JP5557832B2 (ja) 置換４−ヒドロキシピリジン−５−カルボキサミド
EP2257169B1 (en) Tetrahydrothieno pyridines
EP2257171B1 (en) Tetrahydro-1h-pyrrolo-fused pyridones
US10000501B2 (en) Inhibitors of HIF prolyl hydroxylase
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
US9006433B2 (en) Substituted pyrimidines
JP2012532127A (ja) 置換４−ヒドロキシピリミジン−５−カルボキサミド
JP2012530136A (ja) 置換−１，３，８−トリアザスピロ［４．５］デカン−２，４−ジオン
ES2412779T3 (es) Compuestos de espiroazaindol como inhibidores de HIF propilhidroxilasa
US10208060B2 (en) Inhibitors of HIF prolyl hydroxylase
WO2011130908A1 (en) Substituted pyrimidines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120210

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120702

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20120808

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140311